DOI: https://dx.doi.org/10.18565/epidem.2021.11.1.6-11
Koroleva M.A., Gritsay M.I., Koroleva I.S.
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia
1. Visintin C., Mugglestone M.A., Fields E.J., Jacklin P., Murphy M.S., Pollard A.J. Management of bacterial meningitis and meningococcal septicaemia in children and young people: summary of NICE guidance. BMJ 2010; 340: 3209. https://doi.org/10.1136/bmj.c3209 2. Pollard A.J., Nadel S., Ninis N., Faust S.N., Levin M. Emergency management of meningococcal disease: eight years on. Arch. Dis. Child. 2007; 92: 283–6. https://doi.org/10.1136/adc.2006.102384 3. Read R.C. Neisseria meningitidis and meningococcal disease: Recent discoveries and innovations. Curr. Opin. Infect. Dis. 2019. https://doi.org/10.1097/QCO.0000000000000606 4. Beebeejaun K., Parikh S.R., Campbell H., Gray S., Borrow R., Ramsay M.E. et al. Invasive meningococcal disease: Timing and cause of death in England, 2008–2015. J. Infect. 2020; 80: 286–90. https://doi.org/10.1016/j. jinf.2019.12.008 5. ECfDPaC (ECDC). Invasive meningococcal disease: Annual Epidemiological Report for 2017, on ECDC 2019. https://www.ecdc. europa.eu/sites/ default/files/documents/AER_for_2017-invasive-meningococcal-disease.pdf 6. Campbell H., Borrow R., Arumugam C., Ramsay M., Ladhani S.N. Invasive meningococcal disease as a cause of sudden and unexpected death in a teenager: The public health importance of confirming the diagnosis. J. Infect. 2019. https://doi.org/10.1016/j.inf.2018.11.004 7. Wang B., Santoreneos R., Giles L., Haji Ali Afzali H., Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. Vaccine 2019. https://doi.org/10. 1016/j.vaccine.2019.04.020 8. Viner R.M., Booy R., Johnson H., Edmunds W.J., Hudson L., Bedford H. et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012; (11): 774–83. https://doi.org/10.1016/S1474-4422(12)70180-1 9. Dastouri F., Hosseini A., Haworth E., Khandaker G., Rashid H., Booy R. Complications of Serogroup B Meningococcal Disease in Survivors: A Review. Infect. Disord – Drug Targets 2015; 14: 205–12. https://doi.org/10.2174/1871526515999150320155614 10. Ladhani S.N., Flood J.S., Ramsay M.E., Campbell H., Gray S.J., Kaczmarski E.B. et al. Invasive meningococcal disease in England and Wales: Implications for the introduction of new vaccines. Vol. 30. Elsevier; 2012. https://doi.org/10.1016/j.vaccine.2012.03.011 11. Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004. https://doi.org/10.1016/S0140-6736(04)16725-1 12. Campbell H., Saliba V., Borrow R., Ramsay M., Ladhani S.N. Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015. Eurosurveillance 2015. https://doi.org/10.2807/1560-7917.ES2015.20.28.21188 13. Parikh S.R,. Campbell H., Bettinger J.A., Harrison L.H., Marshall H.S., Martinon-Torres F. et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J. Infect. 2020. https://doi.org/10.1016/j.jinf.2020.05.079 14. Stanton M.C., Taylor-Robinson D., Harris D., Paize F., Makwana N,. Hackett S.J. et al. Meningococcal disease in children in Merseyside, england: A 31 year descriptive study. PLoS One 2011. https://doi.org/10.1371/journal.pone.0025957 15. Darton T., Guiver M., Naylor S., Jack D.L., Kaczmarski E.B., Borrow R. et al. Severity of meningococcal disease associated with genomic bacterial load. Clin. Infect. Dis. 2009. https://doi.org/10.1086/596707 16. Borrow R., Alarcon P., Carlos J., Caugant D.A., Christensen H., Debbag R.et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev. Vaccines 2017. https://doi.org/10.1080/14760584.2017. 1258308
Maria А. Koroleva, Cand. Med. Sci., Senior Researcher, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; korolevamaria389@mail.ru; http://orcid.org/0000-0002-2714-1191
Maria I. Gritsay, Graduate Student, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis, Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being, Moscow, Russia; maria-griz@mail.ru
Irina S. Koroleva, MD, Head, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; irina-korol@yandex.ru; http://orcid.org/0000-0003-0578-146X